OverviewSuggest Edit

Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Its pipeline is focused on small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth inhibition. Verastem Oncology develops VS-6766, an orally available small molecule RAF/MEK inhibitor that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK; and defactinib, a targeted inhibitor of FAK that is a non-receptor tyrosine kinase encoded by the protein tyrosine kinase-2 (PTK-2) gene that is involved in cellular adhesion and, in cancer, metastatic capability.

TypePublic
Founded2010
HQNeedham, MA, US
Websiteverastem.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Dec 2020)48(-64%)
Revenue (FY, 2020)$88.5 M(+408%)
Share Price (Sept 2021)$2.6(+2%)
Cybersecurity ratingAMore

Key People/Management at Verastem Oncology

Brian Stuglik

Brian Stuglik

Chief Executive Officer, Director
Daniel Paterson

Daniel Paterson

President and Chief Operating Officer
Rob Gagnon

Rob Gagnon

Chief Business and Financial Officer
Jonathan Pachter

Jonathan Pachter

Chief Scientific Officer
Hagop Youssoufian

Hagop Youssoufian

Head of Medical Strategy
Cathy Carew

Cathy Carew

Chief Organizational Effectiveness Officer
Show more

Verastem Oncology Office Locations

Verastem Oncology has offices in Needham and Walsrode
Needham, MA, US (HQ)
117 Kendrick St
Walsrode, DE
Lange Str. 70
Show all (2)

Verastem Oncology Financials and Metrics

Verastem Oncology Revenue

Embed Graph
View revenue for all periods
Verastem Oncology's revenue was reported to be $88.52 m in FY, 2020 which is a 407.1% increase from the previous period.
USD

Revenue (Q2, 2021)

500.0k

Net income (Q2, 2021)

(16.9m)

EBIT (Q2, 2021)

(15.9m)

Market capitalization (14-Sept-2021)

452.1m

Closing stock price (14-Sept-2021)

2.6

Cash (30-Jun-2021)

25.0m

EV

430.0m
Verastem Oncology's current market capitalization is $452.1 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

26.7m17.5m88.5m

Revenue growth, %

(35%)407%

Cost of goods sold

165.0k2.8m33.7m

Gross profit

26.6m14.6m54.8m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

1.7m3.1m9.0m5.1m4.3m78.6m1.0m500.0k

Cost of goods sold

158.0k769.0k763.0k887.0k785.0k32.1m

Gross profit

1.5m2.4m8.3m4.2m3.5m46.6m

Gross profit Margin, %

91%75%92%82%82%59%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

129.9m43.5m67.8m

Accounts Receivable

306.0k2.5m239.0k

Prepaid Expenses

3.0m3.8m3.5m

Inventories

327.0k3.1m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

91.5m113.1m103.3m135.1m125.3m140.5m35.5m25.0m

Accounts Receivable

558.0k1.4m2.2m3.3m1.5m5.7m1.1m476.0k

Prepaid Expenses

4.1m3.4m4.0m5.9m6.6m3.0m5.5m6.1m

Inventories

306.0k294.0k478.0k4.4m6.3m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(72.4m)(149.2m)(67.7m)

Depreciation and Amortization

1.4m2.0m1.3m

Inventories

(327.0k)(2.8m)3.1m

Accounts Payable

1.0m(598.0k)(8.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(38.1m)(80.3m)(110.4m)(38.0m)(61.0m)(47.9m)(15.0m)(31.9m)

Depreciation and Amortization

505.0k1.0m1.5m486.0k974.0k1.2m81.0k146.0k

Inventories

21.0k33.0k(151.0k)(1.3m)(3.2m)3.1m

Accounts Payable

(1.7m)1.3m(1.4m)(2.5m)(7.4m)(5.0m)774.0k(284.0k)
USDFY, 2018

EV/EBIT

-2.5 x

EV/CFO

-3.2 x

Revenue/Employee

224.5k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.2 x

P/E Ratio

(2.5)
Show all financial metrics

Verastem Oncology Operating Metrics

FY, 2020

Phase I/II Trials Products

6

Phase II Trials Products

4
Show all operating metrics

Verastem Oncology Acquisitions / Subsidiaries

Company NameDateDeal Size
Verastem Europe GmbH
Verastem Securities Company

Verastem Oncology Revenue Breakdown

Embed Graph

Verastem Oncology revenue breakdown by business segment: 79.1% from Sale of COPIKTRA License, 17.2% from Product Revenue and 3.7% from Other

Verastem Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Verastem Oncology Online and Social Media Presence

Embed Graph

Verastem Oncology News and Updates

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology announced the grant of options to purchase 16,250 shares of its common stock and the grant of 8,125 restricted stock units (RSUs) to three new employees

Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

Verastem Oncology announced the appointments of Paul Bunn, M.D., and Lesley Solomon to its Board of Directors, adding additional strength in the areas of academic research and business innovation

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference

Verastem announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, its FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGS…

Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

Verastem reported financial results for the three months ended March 31, 2021, highlighted recent progress and outlined key corporate objectives

Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022

Verastem reported financial results for the three months and full year ending December 31, 2020, and highlighted its key corporate objectives for 2021 and early 2022
Show more

Verastem Oncology Blogs

Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Received Breakthrough Therapy Designation for VS-6766 in Combination with Defactinib for the Treatment of Recurrent Low-Grade Serous Ovarian Cancer Following One or More Prior Lines of Therapy Eliminated Substantially All Outstanding Debt; Expected Cash Runway Until at Least 2024 Updated Results

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021 Content Import Tue, 07/27/2021 - 07:01 Verastem Oncology Announces Updated Phase 1/2 FRAME Study…

Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

Transaction Preserves $31.2 Million in Cash Cash Runway Expected Until at Least 2024 to Deliver on Current Programs BOSTON --(BUSINESS WIRE)--Jul. 19, 2021-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today

Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

BOSTON --(BUSINESS WIRE)--Jun. 24, 2021-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the appointments of Paul Bunn , M.D., and Lesley Solomon to its Board of Directors, adding

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference Content Import Tue, 05/25/2021 - 07:01 Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference May 25, 2021 at 7:00 AM EDT This release is a backfill from…

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile BOSTON --(BUSINESS WIRE)--May 24, 2021-- Verastem, Inc.
Show more

Verastem Oncology Frequently Asked Questions

  • When was Verastem Oncology founded?

    Verastem Oncology was founded in 2010.

  • Who are Verastem Oncology key executives?

    Verastem Oncology's key executives are Brian Stuglik, Daniel Paterson and Rob Gagnon.

  • How many employees does Verastem Oncology have?

    Verastem Oncology has 48 employees.

  • What is Verastem Oncology revenue?

    Latest Verastem Oncology annual revenue is $88.5 m.

  • What is Verastem Oncology revenue per employee?

    Latest Verastem Oncology revenue per employee is $1.8 m.

  • Who are Verastem Oncology competitors?

    Competitors of Verastem Oncology include Tanvex Biopharma, Novartis and Relay Therapeutics.

  • Where is Verastem Oncology headquarters?

    Verastem Oncology headquarters is located at 117 Kendrick St, Needham.

  • Where are Verastem Oncology offices?

    Verastem Oncology has offices in Needham and Walsrode.

  • How many offices does Verastem Oncology have?

    Verastem Oncology has 2 offices.